OCS-01 in Phase 2: Topical Treatment for DME

Ramin Tadayoni, MD, PhD

Show Description +

Ramin Tadayoni, MD, PhD, explains the unique structure and formulation of OCS-01 (Oculis), a topical treatment for DME. Dr. Tadayoni also reviews the 150-patient phase 2 trial that evaluated changes in central macular thickness and BCVA in patients with DME who underwent therapy with OCS-01.

Posted: 10/16/2020

Keywords:

Clinical Cases

•

Diabetic macular edema, DME

•

macular thickness

•

retina-meeting-recap

Up Next

Name: OCS-01 in Phase 2: Topical Treatment for DME
Uploaded: 2020-10-16T12:34:00+00:00
Description: Ramin Tadayoni, MD, PhD, explains the unique structure and formulation of OCS-01 (Oculis), a topical treatment for DME. Dr. Tadayoni also reviews the 150-patient phase 2 trial that evaluated changes in central macular thickness and BCVA in patients with DME who underwent therapy with OCS-01.